Research programme: dronabinol controlled-release - Aphios Corporation

Drug Profile

Research programme: dronabinol controlled-release - Aphios Corporation

Alternative Names: APH-0802; Cannabinoid therapeutics - Aphios Corporation; nanoTHC

Latest Information Update: 08 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphios Corporation
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cachexia; Cancer pain; Drug abuse; Multiple sclerosis; Nausea and vomiting; Pain

Highest Development Phases

  • Preclinical Cachexia; Cancer pain; Chemotherapy-induced nausea and vomiting; Drug abuse; Multiple sclerosis; Pain

Most Recent Events

  • 15 Nov 2013 Preclinical trials in Multiple sclerosis in USA (PO)
  • 15 Nov 2013 Preclinical trials in Pain (in patients with AIDS) in USA (PO)
  • 02 Feb 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top